Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2025	Jun. 30, 2024	Jun. 30, 2025	Jun. 30, 2024
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)
Services	$ 161,778	$ 116,090	$ 277,254	$ 155,866
Product	244,910	279,707	375,819	411,466
Total Revenues	406,688	395,797	653,073	567,332
Operating Expenses
Research and development	2,720,207	3,715,797	5,327,321	8,345,324
General and administrative	2,940,754	2,284,041	5,184,116	4,537,784
Sales and marketing	1,043,534	1,386,378	1,960,833	3,059,147
Total Operating Expenses	6,704,495	7,386,216	12,472,270	15,942,255
Operating Loss	(6,297,807)	(6,990,419)	(11,819,197)	(15,374,923)
Other Income (Expenses)
Grant income	75,991	0	197,227	0
Gain (Loss) on disposal of fixed assets	330	(33,498)	330	(33,498)
Interest income	160	450	318	9,104
Interest expense	(123,356)	(81,182)	(220,025)	(158,415)
Amortization of debt discount	(325,305)	0	(325,305)	0
Gain on change in fair value of derivative liability	418,681	0	418,681	0
Gain (loss) on change in fair value of warrant liability	(62,764)	44,474	(42,726)	25,552
Total Other Income (Expenses)	(16,263)	(69,756)	28,500	(157,257)
Net Loss	(6,314,070)	(7,060,175)	(11,790,697)	(15,532,180)
Net Loss Attributable to Non-Controlling Interest	29,992	74,629	82,860	179,246
Net Loss Attributable to VolitionRx Limited Stockholders	(6,284,078)	(6,985,546)	(11,707,837)	(15,352,934)
Other Comprehensive Income (Loss)
Foreign currency translation adjustments	(575,996)	23,024	(829,925)	38,312
Net Comprehensive Loss	$ (6,890,066)	$ (7,037,151)	$ (12,620,622)	$ (15,493,868)
Net Loss Per Share - Basic and Diluted Attributable to VolitionRx Limited stockholders	$ (0.06)	$ (0.08)	$ (0.12)	$ (0.19)
Weighted Average Shares Outstanding- Basic and Diluted	102,654,095	82,669,335	99,611,974	82,312,161